PubMed Health⌕ Search

Biomedical subjects

A Pizarro Portillo

Publications and source records attributed to A Pizarro Portillo.

4 recordsLinked to original sources
PubMed2005

[Short-term evaluation of risk factor control and therapeutic prescription in secondary prevention of cardiovascular diseases].

INTRODUCTION: Quantify risk factor control and compliance of present therapeutic recommendations in the two months following an acute myocardial infarction (AMI) or ischemic stroke. MATERIAL AND METHODS: Cross-sectional, descriptive study of risk factors and treatments prescribed on discharge after AMI or stroke. RESULTS: A total of 68% of 122 patients (65.6% AMI; 22.1% women; mean age: 64.9), had controlled BP; 70.1% BMI < 30 kg/m2; 54.1% LDL-cholesterol < 100 mg/dl. Controlled BP (78.7% versus 50%) and adequate LDL-cholesterol (62.3% versus 20.5%) were greater after AMI than after stroke (p < 0.001). ACEI/ARA II prescribed after AMI: 30% (p < 0.001). After AMI, 26.2% without beta blocker (only 8.8% contraindicated). HbA1c < 7% in 55.5% of diabetics; BP control inferior to non-diabetics (p < 0.001). DISCUSSION: Short term control of the risk factors after cardiovascular episode and prescription on hospital discharge are improvable, above all after a stroke.

Adult↗
PubMed2001

[Analysis of prognostic factors for mortality in bacteremia and fungemia at a university hospital. Experience of 10 years].

OBJECTIVE: The objective of this study was to determine the prognostic factors in relationship to evolution to death of bacteremia-fungemia (BF) episodes occurred in 1986 and to compare them with the results obtained ten years later in 1996. PATIENTS AND METHODS: Prospective study of all BF episodes observed at Hospital Universitario La Princesa, Madrid, during the 1985-1986 and 1996-1997 periods. The same definitions were used for the two study periods. The univariate analysis of results was performed with the chi square test and variables with statistical significance with p < 0.10 in the multivariate analysis with the logistic regression model. RESULTS: A total of 984 episodes were analyzed. There was an increased incidence per 1,000 admissions from 23.58 to 28.44. A change in the relationship of nosocomial acquisition (55.5%-42.6%) to community-acquired episodes (44.1%-57.4%) and an increase in gram-positive organisms (39%-48.6%) compared with gram-negative organisms (53.4%-41.8%) was observed. The organisms recovered most frequently in both periods were Escherichia coli and coagulase-negative Staphylococcus. An overall decrease of mortality rate from 26.2% down to 15.9% (OR: 4.52) was noted. Independent factors with poor prognosis in the first period included age over 60 years (OR: 4.52), underlying disease (OR: 2.79; more than one OR: 6.53), respiratory source (OR: 3.86), DIC (OR: 4.79), hypotension (OR: 3.19); as for the second period, the corresponding independent factors included age > 60 years (OR: 6.48), nosocomial acquisition (OR: 2.62), DIC (OR: 18.7), hypotension (OR: 3.07), and inadequate surgical treatment (OR: 7.61). CONCLUSIONS: In the last ten years the incidence of BF episodes has increased. In contrast, mortality rate has decreased. Factors with poor prognosis, including age > 60, DIC, and hypotension, still persist.

Adult↗
PubMed1997

[Treatment with interferon of chronic active hepatitis in patients with HIV infection].

Clinical records of 14, CD4 cell counts > 400/mm3, mild symptoms or asymptomatic, HIV infected patients and with chronic active hepatitis (identified by hepatic biopsy) were under review. Four of them were infected with HBV, 8 with HCV, 1 with HDV and other one with HBV + HCV + HDV. They were treated with alpha interferon for 6 months. Effectiveness was evaluated. It was found that in 4 (50%) of HCV infected patients transaminases raised normal value two of them remained with normal values at the end of review (22 and 48 months of follow-up). All HBV infected patients (4) normalized transaminases. Three of them lost HBeAg, that persisted through 38 months of follow-up. It was found too, whose did not improved with 6 months treatment did not benefit with a longer treatment. Therefore, HIV infected patients uncompromised (CD4+ > 400/mm3) and with chronic active hepatitis were benefited by interferon treatment (57%). Reversal of HBeAg was remarkable.

Adult↗